SCHEMBL2299271

SCHEMBL2299271

CNC(=O)c1cc(N)ccc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.67
KDM4E B2RXH2 3/20 0.60
TDP1 Q9NUW8 3/20 0.60
ALDH1A1 P00352 2/20 0.60
CYP3A4 P08684 2/20 0.60
MEN1 O00255 2/20 0.60
THRB P10828 2/20 0.60
RECQL P46063 2/20 0.60
KMT2A Q03164 2/20 0.60
CASP1 P29466 2/20 0.60
ALOX15 P16050 2/20 0.60
HSD17B10 Q99714 2/20 0.60
TNF P01375 1/20 0.60
HSPD1 P10809 1/20 0.60
CYP2C9 P11712 1/20 0.60
HPGD P15428 1/20 0.60
CYP2C19 P33261 1/20 0.60
PTGS2 P35354 1/20 0.60
KDR P35968 1/20 0.60
BRCA1 P38398 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12216548 0.85 GAA (0.62) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL25635486 0.82 KMT2A (0.57) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL732923 0.82 ALOX5 (0.64) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL14193085 0.82 BRAF (0.61) ALOX5TDP1ALDH1A1CYP3A4MEN1
SCHEMBL15894582 0.81 ALOX5 (0.63) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL31079645 0.81 CASP1 (0.45) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL10156668 0.81 CASP1 (0.45) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL9363663 0.80 ALOX5 (1.00) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL1977469 0.80 ALOX5 (0.61) ALOX5KDM4ETDP1ALDH1A1CYP3A4
SCHEMBL29779139 0.80 EGFR (0.62) ALOX5KDM4EALDH1A1PTGS2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US disclosed
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 US disclosed
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 US disclosed
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
US-20100048890-A1 CONJUGATED SMALL MOLECULES DISCOVERX CORPORATION 2010-02-25 US disclosed
EP-0345728-B1 Dye composition for keratinous fiber KAO CORP (JP) 1994-09-14 EP disclosed
US-5047066-A Dye composition for keratinous fibers containing a 2-substituted 4-aminophenol compound as a developer, and a coupling substance KAO CORPORATION (JP) 1991-09-10 US disclosed
EP-0345728-A2 Dye composition for keratinous fiber Kao Corporation (JP) 1989-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048890-A1 CONJUGATED SMALL MOLECULES ERBB2, ALK, ACP1 ALOX5 2879/4885KDM4E 1118/4885TDP1 3880/4885
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION KRT18, ARSA, SQOR ALOX5 195/4885KDM4E 1417/4885TDP1 3636/4885
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I ALOX5 2138/4885KDM4E 816/4885TDP1 2812/4885
US-20230045031-A1 Diarylamide Compound and Application Thereof SLC14A1, SLC28A1, SLC28A2 ALOX5 4736/4885KDM4E 3421/4885TDP1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.